Research programme: neurodegenerative disorders therapeutics - Neurim Pharmaceuticals

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Neurim Pharmaceuticals

Alternative Names: Neu-240; Neurodegeneration drug discovery - Neurim Pharmaceuticals; Neurodegeneration programme - Neurim Pharmaceuticals

Latest Information Update: 08 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurim Pharmaceuticals
  • Class
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyskinesias; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 13 Dec 2012 Preclinical trials in Dyskinesia in Israel (unspecified route)
  • 13 Dec 2012 Preclinical trials in Parkinson's disease (adjunctive treatment) in Israel (unspecified route)
  • 01 Jan 2012 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top